Biosign Technologies Inc BITKF

RE: interesting article

[facanadian1]

As a Canadian-developed drug, Biolyse’s product is a rarity, says Bob Reichert, PhD, a member of the Expert Committee on Plant Products and employed with the Industrial Research Assistance Program of the National Research Council of Canada. For example, he says, during the last 10 years, only six new molecular entities have been discovered in Canada and commercialized: Vioxx® and Singulair® (Merck Frosst Canada & Co.), Visudyne® (QLT Inc.), Epivir® or 3TC (Shire BioChem Inc.), Levulan® PDT (DUSA Pharmaceuticals Inc.), and Diab II™ (Biotech Holdings Ltd.).